Pharmacological inhibition of HIF-1α and ROS, two main drivers of glycolysis in CAFs, partially revert the glycolytic phenotype by rescuing IDH3α and downregulating MCT4 expression in fibroblasts and reduce aggressiveness of ADT carcinoma cells. The gene discussed is HIF1A; the disease is carcinoma.